Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone vs Glyburide Liver Safety in Type 2 Diabetes
NCT00494312Phase 4Completed
- Sponsor
- Takeda
- Start
- Oct 2000
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Incidence of alanine aminotransaminase elevation greater than 3 times the upper limit of normal at 156 weeks. Started Oct 2000; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00494312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494312.